134 related articles for article (PubMed ID: 38454822)
21. Genuine- and induced-oligometastatic castration-resistant prostate cancer: clinical features and clinical outcomes after progressive site-directed therapy.
Yoshida S; Takahara T; Arita Y; Toda K; Yamada I; Tanaka H; Yokoyama M; Matsuoka Y; Yoshimura R; Fujii Y
Int Urol Nephrol; 2021 Jun; 53(6):1119-1125. PubMed ID: 33452956
[TBL] [Abstract][Full Text] [Related]
22. Radiotherapy in metastatic castration resistant prostate cancer patients with oligo-progression during abiraterone-enzalutamide treatment: a mono-institutional experience.
Valeriani M; Marinelli L; Macrini S; Reverberi C; Aschelter AM; De Sanctis V; Marchetti P; Tronnolone L; Osti MF
Radiat Oncol; 2019 Nov; 14(1):205. PubMed ID: 31727093
[TBL] [Abstract][Full Text] [Related]
23. Patterns of recurrence in genuine and induced oligometastatic castration-resistant prostate cancer treated with progressive site-directed therapy.
Yoshida S; Takahara T; Arita Y; Toda K; Kimura K; Fujiwara M; Tanaka H; Yokoyama M; Matsuoka Y; Yoshimura R; Fujii Y
Int J Urol; 2023 Feb; 30(2):204-210. PubMed ID: 36314128
[TBL] [Abstract][Full Text] [Related]
24. The presence of lymph node metastases and time to castration resistance predict the therapeutic effect of enzalutamide for castration-resistant prostate cancer.
Oka T; Hatano K; Okuda Y; Yamamoto A; Uemura T; Yamamichi G; Tomiyama E; Ishizuya Y; Yamamoto Y; Kato T; Kawashima A; Fujita K; Nonomura N
Int J Clin Oncol; 2023 Mar; 28(3):427-435. PubMed ID: 36580184
[TBL] [Abstract][Full Text] [Related]
25. Rapidly decreasing level of prostate-specific antigen during initial androgen deprivation therapy is a risk factor for early progression to castration-resistant prostate cancer: A retrospective study.
Ji G; Song G; Huang C; He S; Zhou L
Medicine (Baltimore); 2017 Sep; 96(36):e7823. PubMed ID: 28885333
[TBL] [Abstract][Full Text] [Related]
26. Progression-directed Therapy for Oligoprogression in Castration-refractory Prostate Cancer.
Berghen C; Joniau S; Ost P; Poels K; Everaerts W; Decaestecker K; Haustermans K; Devos G; De Meerleer G
Eur Urol Oncol; 2021 Apr; 4(2):305-309. PubMed ID: 31558422
[TBL] [Abstract][Full Text] [Related]
27. Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring.
Saad F; Sternberg CN; Efstathiou E; Fizazi K; Modelska K; Lin X; Sugg J; Steinberg J; Noerby B; Shore ND; Hussain M
Eur Urol; 2020 Dec; 78(6):847-853. PubMed ID: 33010985
[TBL] [Abstract][Full Text] [Related]
28. Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies.
Nadal R; Tsai HL; Sinibaldi VJ; Paller CJ; Antonarakis ES; Denmeade SR; Carducci MA; Eisenberger MA
Prostate; 2016 Apr; 76(5):512-20. PubMed ID: 26689606
[TBL] [Abstract][Full Text] [Related]
29. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.
Hussain M; Fizazi K; Saad F; Rathenborg P; Shore N; Ferreira U; Ivashchenko P; Demirhan E; Modelska K; Phung D; Krivoshik A; Sternberg CN
N Engl J Med; 2018 Jun; 378(26):2465-2474. PubMed ID: 29949494
[TBL] [Abstract][Full Text] [Related]
30. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
31. The Role of Fast and Deep PSA Response in Castration-sensitive Prostate Cancer.
Iacovelli R; Ciccarese C; Caffo O; De Giorgi U; Basso U; Tucci M; Mosillo C; Maruzzo M; Maines F; Casadei C; Milella M; Tortora G
Anticancer Res; 2022 Jan; 42(1):165-172. PubMed ID: 34969722
[TBL] [Abstract][Full Text] [Related]
32. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: Multicenter validation in patients from the Chinese Prostate Cancer Consortium.
Pei X; Wu K; Sun Y; Gao X; Gou X; Xu J; Gao F; He D; Li L;
Urol Oncol; 2020 Jan; 38(1):2.e11-2.e17. PubMed ID: 31672485
[TBL] [Abstract][Full Text] [Related]
33. The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer.
Schweizer MT; Zhou XC; Wang H; Bassi S; Carducci MA; Eisenberger MA; Antonarakis ES
Eur Urol; 2014 Oct; 66(4):646-52. PubMed ID: 24491307
[TBL] [Abstract][Full Text] [Related]
34. Serum alkaline phosphatase differentiates prostate-specific antigen flare from early disease progression after docetaxel chemotherapy in castration-resistant prostate cancer with bone metastasis.
Han KS; Hong SJ
J Cancer Res Clin Oncol; 2014 Oct; 140(10):1769-76. PubMed ID: 24858569
[TBL] [Abstract][Full Text] [Related]
35. Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer.
Hammerich KH; Donahue TF; Rosner IL; Cullen J; Kuo HC; Hurwitz L; Chen Y; Bernstein M; Coleman J; Danila DC; Metwalli AR
Urol Oncol; 2017 Jul; 35(7):460.e21-460.e28. PubMed ID: 28410987
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic Effect of Ethinylestradiol in Castration-resistant Prostate Cancer.
Nakano T; Kadono Y; Iwamoto H; Yaegashi H; Iijima M; Kawaguchi S; Nohara T; Shigehara K; Izumi K; Mizokami A
Anticancer Res; 2020 Apr; 40(4):2291-2296. PubMed ID: 32234928
[TBL] [Abstract][Full Text] [Related]
37. Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid.
Saad F; Segal S; Eastham J
Eur Urol; 2014 Jan; 65(1):146-53. PubMed ID: 22633317
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and Safety of Carboplatin Plus Paclitaxel as the First-, Second-, and Third-line Chemotherapy in Men With Castration-resistant Prostate Cancer.
Fujiwara M; Akamatsu S; Sumiyoshi T; Segawa T; Mizuno K; Yoshino T; Goto T; Sawada A; Saito R; Kobayashi T; Yamasaki T; Inoue T; Ogawa O
Clin Genitourin Cancer; 2019 Oct; 17(5):e923-e929. PubMed ID: 31307917
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of Ethinylestradiol Re-challenge for Metastatic Castration-resistant Prostate Cancer.
Onishi T; Shibahara T; Masui S; Sugino Y; Higashi S; Sasaki T
Anticancer Res; 2016 Jun; 36(6):2999-3004. PubMed ID: 27272817
[TBL] [Abstract][Full Text] [Related]
40. Effective and Safe Administration of Low-Dose Estramustine Phosphate for Castration-Resistant Prostate Cancer.
Inoue T; Ogura K; Kawakita M; Tsukino H; Akamatsu S; Yamasaki T; Matsui Y; Segawa T; Sugino Y; Kamoto T; Kamba T; Tanaka S; Ogawa O
Clin Genitourin Cancer; 2016 Feb; 14(1):e9-e17. PubMed ID: 26433627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]